The MiMedx Management and Sales Team
MiMedx Group, Inc. was incorporated on February 28, 2008. Its initial assets consisted of our HydroFix® and CollaFixTM technology platforms.
On January 5, 2011, the company acquired all of the outstanding equity interests in Surgical Biologics, LLC, and subsequently consolidated the corporate offices and operating facilities in Kennesaw, Georgia. This strategic acquisition brought together amnion tissue processing technology with MiMedx®'s experienced management team and extensive distribution network in order to position the company for market opportunities across multiple areas of medicine. Surgical Biologics developed allografts and other products processed from human amniotic membrane that can be used for a wide range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon protection, spine surgery, burn treatment, and many other types of procedures that require the repair of a patient’s integumental (native) tissue.
At the time of the acquisition, Surgical Biologics distributed tissue in several different membrane sub-segments, such as ocular, dental, and spine. Early 2011, MiMedx® launched AmnioFix® for applications in spinal procedures. AmnioFix® is used as a barrier membrane that reduces scar tissue formation between the dura and soft tissue. During 2011, the company launched EpiFix® nationwide. EpiFix® is an allograft specifically processed for a wide variety of wound care patients suffering from diabetic ulcers, pressure ulcers, venous ulcers, or arterial ulcers.
The company further expanded its amnion product offering in 2011 with the introduction of AmnioFix® Wrap for both nerve and tendon protection applications. The same year, the company announced the launch of AmnioFix® Injectable, which is an allograft composed of micronized amniotic tissue, uniquely processed to optimize performance and ease of use.
PURION® Processed Tissue History
Amniotic tissue use has been documented as far back as the early 1900s, and over the past several years has seen resurgence. After nearly two decades of human tissue experience, the Surgical Biologics founders had the vision to apply modern proprietary processing techniques to placental tissue to create unique ophthalmic, spinal, orthopedic, and dental implants.